Olimel N12e (Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin)

Olimel N12e provides amino acid supplementation for conditions that increase protein catabolism or impair nutrient absorption.

• Critical illness: helps maintain nitrogen balance and supports tissue repair.
• Post‑operative recovery: aids in wound healing and muscle preservation.
• Severe malnutrition: contributes to rebuilding lean body mass when oral intake is insufficient.

• The amino acid blend supplies substrates for protein synthesis, stimulates the mTOR pathway and supports hepatic urea cycle function, thereby enhancing nitrogen retention and facilitating tissue regeneration in catabolic states.

Amino acid solutions are generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Mild nausea or vomiting
• Transient headache
• Slight increase in serum urea nitrogen
• Mild infusion site erythema
• Temporary rise in serum potassium
• Mild metabolic alkalosis

Serious or Rare Side Effects

• Anaphylactic reaction
• Severe hyperkalemia
• Acute respiratory distress syndrome (ARDS)
• Thrombophlebitis at infusion site
• Sepsis related to contaminated product
• Severe metabolic acidosis

When using Olimel N12e, clinicians should consider patient‑specific factors and follow standard infusion protocols.

• Renal impairment: adjust infusion rate and monitor electrolytes.
• Hepatic dysfunction: observe for altered ammonia levels.
• Electrolyte imbalance: check serum potassium and calcium before administration.
• Hyperglycaemia risk: monitor blood glucose in diabetic patients.
• Allergic history: assess for prior reactions to amino acid preparations.
• Store at ambient temperature: keep in original container, protect from moisture and light.

Olimel N12e may interact with other intravenous therapies and metabolic modulators.

Major Interactions (Avoid)

• High‑dose potassium chloride: risk of severe hyper‑kalemia.
• Sodium bicarbonate bolus: may cause rapid shifts in acid‑base balance.
• Certain antifungal azoles: can alter amino acid metabolism.

Moderate Interactions (Monitor Closely)

• Loop diuretics: enhance potassium loss, requiring electrolyte monitoring.
• Insulin therapy: may potentiate hypoglycaemia when combined with dextrose‑containing solutions.
• Parenteral lipid emulsions: compete for infusion line space, increasing risk of incompatibility.